Absence of protective effect of renin-angiotensin system inhibitors on atrial fibrillation development: Insights from the Canadian Trial of Atrial Fibrillation (CTAF)
Maryse Palardy(Montreal Heart Institute), Denis Roy(Montreal Heart Institute), Normand Racine(Montreal Heart Institute), Karine Tétreault(Montreal Heart Institute), Michel White(Montreal Heart Institute), Mario Talajic(Montreal Heart Institute), Farida Dabouz(Montreal Heart Institute), Stanley Nattel(Montreal Heart Institute), Jean‐Claude Tardif(Montreal Heart Institute), Anique Ducharme(Montreal Heart Institute)
Cited by 21
Related Papers
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
|New England Journal of Medicine|2018|3.2k
2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation
|Heart Rhythm|2017|2.7k
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
|New England Journal of Medicine|2015|2.3k
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
|New England Journal of Medicine|2012|2k